Abstract
The treatment options for the patient with advanced prostate cancer are limited. Due to the recent advances in the understanding of the molecular biology of prostate cancer, the easy accessibility of the gland for injection, and the availability of gene promoters that can provide tissue specific expression of therapeutic gene sequences, gene therapy for prostate cancer is rapidly advancing. Many potential approaches for prostate cancer gene therapy have been identified, with a few of these already entering Phase I clinical trials. This review will discuss the basis of prostate cancer gene therapy, look at the potential approaches, and will compare the different vectors that can be used to deliver the therapeutic genes to the prostate tumor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Naitoh, J., Belldegrun, A. Gene therapy for prostate cancer. Prostate Cancer Prostatic Dis 1, 189–196 (1998). https://doi.org/10.1038/sj.pcan.4500242
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500242
